Biotest GmbH KGaA (LTS:0N6Z) Research & Development: £ Mil (TTM As of . 20)


What is Biotest GmbH KGaA Research & Development?

Biotest GmbH KGaA LTS:0N6Z Research & Development is £ Mil as of . 20.

Research & Development is the aggregate amount of research and development expenses during the year. Biotest GmbH KGaA's Research & Development for the six months ended in . 20 was £0.00 Mil. Biotest GmbH KGaA does not have enough years/quarters to calculate the Research & Development for the trailing twelve months (TTM) ended in . 20.

Biotest GmbH KGaA  (LTS:0N6Z) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Biotest GmbH KGaA Research & Development Related Terms

Biotest GmbH KGaA Research & Development Historical Data

* Premium members only.

The historical data trend for Biotest GmbH KGaA's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biotest GmbH KGaA Research & Development Chart

Biotest GmbH KGaA Annual Data
Trend
Research & Development

Biotest GmbH KGaA Semi-Annual Data
Research & Development

Biotest GmbH KGaA Research & Development Calculation

This is the expense the company spent on research and development.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of £ Mil mean?
Biotest GmbH KGaA (LTS:0N6Z) has a Research & Development of £ Mil as of . 20. Research and development expense is the total cost for research and development activities. View historical data on Biotest GmbH KGaA and its competitors.
Is Biotest GmbH KGaA's Research & Development too high?
Biotest GmbH KGaA's current Research & Development is £ Mil.
How does Biotest GmbH KGaA's Research & Development compare to ?
Biotest GmbH KGaA's Research & Development of £ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Biotest GmbH KGaA and its competitors. Biotest GmbH KGaA's current Research & Development is £ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotest GmbH KGaA stock overvalued right now?
Biotest GmbH KGaA (LTS:0N6Z) has a current Research & Development of £ Mil. The current Research & Development is £ Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Biotest GmbH KGaA (LTS:0N6Z), the current Research & Development is £ Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biotest GmbH KGaA Business Description

Comparable Companies
Biotest GmbH & Co KGaA is a specialist in haematology, clinical immunology, and intensive care medicine. The group develops, manufactures, and markets plasma proteins and biotherapeutic drugs. The group's value chain extends from pre-clinical and clinical development to world-wide marketing and distribution. It manufactures immunoglobulins, clotting factors, and albumins, which are derived from human blood plasma. The group markets its products in Europe, the Middle East, China, Australia, Africa, and the USA.